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Abstract Angina pectoris resulting from myocardial
ischemia afflicts half of all patients with coronary heart
disease (CHD). Chronic angina remains a major public
health burden despite state-of-the-art therapies, and
improvement in survival from myocardial infarction and
CHD has only increased its prevalence. There is growing
experimental and clinical evidence pointing to the anti-
ischemic and anti-anginal properties of statins. Some data
suggest that the degree of anti-ischemic efficacy of
statins may be comparable to the current standard
pharmacologic and mechanical strategies. The pleiotropic
effects of statins are postulated to be primarily respon-
sible for their anti-ischemic and anti-anginal properties.
These include improvement of endothelial function,
enhancement of the ischemic vasodilatory response,
modulation of inflammation, and protection from
ischemia-reperfusion injury. The anti-ischemic effects of
statins further strengthen their role as a crucial compo-
nent of the optimal medical therapy for CHD.
Keywords Lipid-lowering . Statin . Cardiovascular
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Introduction
Coronary heart disease (CHD), the leading cause of death
for both men and women, is highly prevalent, afflicting
nearly 18 million individuals in the United States alone [1].
About half of all patients with CHD experience angina
pectoris. Chronic angina is a common and a very costly
public health burden. Disbursements from angina-related
hospital admissions, coronary procedures, and outpatient
treatment can consume more than 1% of the total health
care expenditure in the United States [2]. Advances in the
management of CHD have dramatically improved the
survival from acute coronary events. Chronic angina is a
recurrent symptom most commonly encountered by these
patients [3]. Ironically, as the number of survivors of
myocardial infarction (MI) increases, so does the preva-
lence of chronic angina.
Angina is a clinical syndrome that is commonly defined
as chest discomfort and related symptoms resulting from
myocardial ischemia. Global or regional myocardial ische-
mia occurs when there is a mismatch between myocardial
oxygen supply and demand, which is most often associated
with significant occlusion of one or more epicardial
coronary arteries [4]. A variety of pharmacologic and
mechanical strategies comprise the current armamentarium
of angina therapy. The standard anti-anginal medications
include the beta-blocker, calcium channel antagonist,
nitrate, and piperazine classes of agents. Mechanical
approaches to anti-anginal management include coronary
revascularization (through either percutaneous or surgical
J. A. Lardizabal
Division of Cardiology, Fresno Medical Education Program,
University of California – San Francisco,
155 N. Fresno St.,
Fresno, CA 93301, USA
P. C. Deedwania
University of California – San Francisco School of Medicine,
San Francisco, CA, USA
P. C. Deedwania (*)
Veterans Affairs Central California Healthcare System, Division
of Cardiology, VACCHS Medical Center,
2615 E Clinton Avenue,
Fresno, CA 93703, USA
e-mail: pdeedwania@fresno.ucsf.edu
Curr Atheroscler Rep (2011) 13:43–50
DOI 10.1007/s11883-010-0147-y
methods) and non-invasive techniques (such as enhanced
external counterpulsation).
There has been mounting evidence suggesting that the
HMG-CoA reductase inhibitor (statin) class of cholesterol-
lowering agents possesses anti-anginal properties to a
degree of efficacy that may be equivalent to the standard
pharmacologic and mechanical therapies. Understanding
the expanded role of statins in anti-ischemic therapy is
highly relevant, particularly in the context of recent clinical
trial data that show optimal medical therapy alone is at least
as effective as coronary revascularization in the initial
management of patients with chronic stable angina [5•].
Statins and Myocardial Ischemia
The mortality and morbidity benefit of statins in the
management of CHD is well established, both in the
primary and secondary prevention settings. In high-risk
individuals without prior history of CHD, statin therapy, on
average, reduces the risk of MI by 27% and overall
mortality by 7% [6]. In patients with known CHD, it is
estimated that statin treatment reduces total mortality by
16%, CHD mortality by 23%, and major CHD events by
25%, irrespective of baseline cholesterol levels [7].
There is ample literature verifying the favorable influence
of statins on myocardial ischemia in patients with CHD. The
Regression Growth Evaluation Statin Study (REGRESS), for
instance, assessed the effects of pravastatin on transient
myocardial ischemia using ambulatory electrocardiograpy
(AECG) in nearly 800 patients with known CHD who were
on routine anti-anginal therapy [8]. After 2 years of follow-
up, the trial showed that statin therapy significantly reduced
the duration of transient myocardial ischemia and the total
ischemic burden by nearly half compared to baseline,
whereas no improvement was seen with placebo. This
beneficial effect remained even after adjusting for major
ischemic risk factors, as well as revascularization procedures
such as percutaneous coronary intervention (PCI) or coro-
nary artery bypass grafting (CABG). Furthermore, statin
therapy was associated with a significant 42% decrement in
major adverse clinical events.
The Vascular Basis for the Treatment of Myocardial
Ischemia Study randomized 300 dyslipidemic patients with
stable CHD and documented ischemia on stress testing or
AECG into treatment strategies of intensive lipid-lowering
to a target low-density lipoprotein (LDL) of <80 mg/dL
(using high-dose atorvastatin with or without antioxidant
vitamins) or moderate lipid-lowering with diet and low-
dose lovastatin to a target LDL of <130 mg/dL [9].
Ischemia evaluation using AECG and stress testing were
conducted at 6 and 12 months. After 1 year of treatment,
the study showed that statin therapy, using either intensive-
or moderate-dosing strategies, led to significant reductions
in the duration of ischemia and frequency of angina
episodes. Statin treatment also resulted in significant
improvement in exercise time prior to onset of ischemia.
No significant differences in outcomes were seen between
the intensive and moderate lipid-lowering groups despite a
significantly larger lowering of LDL levels in the intensive
arm. It was postulated that there may be a threshold effect
of LDL lowering, below which there is no incremental
improvement in ischemic parameters, and that the lipid
levels achieved with either statin treatment strategies were
below this threshold.
Another major clinical trial, the Study Assessing Goals
in the Elderly (SAGE), compared intensive (atorvastatin
80 mg daily) versus moderate (pravastatin 40 mg daily)
statin therapy in nearly 900 patients with CHD and at least
one documented episode of myocardial ischemia on AECG
[10]. After 12 months of follow-up, the trial demonstrated
that statin therapy, using either intensive-dosing or
moderate-dosing strategies, was associated with a signifi-
cant 37% reduction in the total duration of myocardial
ischemia on AECG, a benefit that was evident as early as
3 months (Fig. 1). Like that seen in the Vascular Basis
Study, there was no significant difference between treat-
ment groups in the total duration of ischemia despite a
greater cholesterol reduction in those who received inten-
sive statin therapy. However, a trend toward fewer
occurences of major adverse cardiac events was also seen
in intensive lipid-lowering arm. Notably, high-dose ator-
vastatin was associated with a significant 77% reduction in
total mortality. These findings suggest that the magnitude of
LDL lowering that is effective in the stabilization of
Fig. 1 Mean total duration of myocardial ischemia on 48-hour
ambulatory electrocardiogram at baseline, month 3, and month 12 in
893 patients treated with either atorvastatin or pravastatin in the Study
Assessing Goals in the Elderly (SAGE) trial [10]. (Adapted from
Deedwania P, Stone PH, Bairey Merz CN, et al.: Effects of intensive
versus moderate lipid-lowering therapy on myocardial ischemia in
older patients with coronary heart disease: results of the Study
Assessing Goals in the Elderly (SAGE). Circulation 2007, 115
(6):700–707; with permission)
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vulnerable plaque and the reduction of clinical events may
be continuous (ie, progressively lower LDL values are
associated with progressively lower cardiac event rates).
When taken in context of the results of the Vascular Basis
Study, it appears that the mechanisms responsible for the
benefits of lipid-lowering therapy in clinical event reduc-
tion may differ from that of ischemia. It is hypothesized
that improvement in ischemia is predominantly related to
improvement in myocardial oxygen supply-and-demand
balance, whereas acute cardiac events are more closely
related to plaque disruption or rupture.
The Anti-Anginal Effects of Statins
The reduction in myocardial ischemic burden seen with
statin therapy is expected to be accompanied by improve-
ment in angina-related symptomatology. The Scandinavian
Simvastatin Survival Study (4S) was one of the earliest
clinical trials that demonstrated the possible anti-anginal
properties of statins [11]. In this study, 4444 dyslipidemic
patients with CHD were randomized to treatment with
either simvastatin or placebo for 5.4 years. Post-hoc
analysis of the 4S trial showed a 26% reduction in new or
worsening angina, as well as a 37% lowering in the
incidence of coronary revascularization, with statin therapy.
Simvastatin treatment significantly decreased the risk of
new or worsening intermittent claudication and bruits as
well.
In 69 patients with symptomatic CHD, a substudy of
the REGRESS trial assessed regional myocardial perfu-
sion and angina functional class at baseline and after
2 years of treatment with either pravastatin or placebo
[12]. The study showed a significant improvement in
regional myocardial perfusion in the patients who received
pravastatin, whereas deterioration was seen in those
assigned to placebo. The enhancement in myocardial
perfusion was accompanied by significant improvement
in angina functional class, and this change was seen only
in patients who received statin therapy. Furthermore, the
group of patients on pravastatin had fewer clinical events
and had better preserved exercise capacity on stress testing
compared to placebo [12].
There is evidence that suggests that the anti-ischemic
efficacy of statins is comparable to that of the more
established pharmacologic anti-anginal agents. The
Double-blind Atorvastatin Amlodipine (DUAAL) trial
enrolled over 300 patients with symptomatic CHD and
compared the anti-ischemic effects of atorvastatin with that
of the calcium channel blocker (CCB) amlodipine, a
standard anti-anginal agent [13]. After 24 weeks of therapy,
both treatment arms induced a comparable, highly signif-
icant reduction in myocardial ischemia documented with
AECG and exercise testing. The marked decrease in the
frequency of angina and nitroglycerin consumption seen
with the CCB was found to be equivalent to that of the
statin, leading to the conclusion that atorvastatin was as
potent an anti-ischemic agent as amlodipine.
There are also data suggesting that aggressive lipid-
lowering therapy is at least as effective as mechanical
reperfusion strategies in low-risk patients with chronic
stable angina. In the Atorvastatin versus Revascularization
Treatment (AVERT) trial, nearly 350 patients with stable
CHD were randomized to either statin therapy or angio-
plasty [14]. After 18 months of follow-up, the study
showed a 35% lower incidence of ischemic events and a
significantly longer time to the first ischemic event in the
group of patients who were assigned to atorvastatin therapy.
Notably, the patients who underwent angioplasty had a 52%
higher incidence of worsening angina compared to those
who received medical therapy alone. Although significant
advances in revascularization techniques have been made
since the AVERT trial, findings from the more recent
Adenosine Sestamibi Post-Infarction Evaluation (INSPIRE)
[15] and Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) [16] trials
provide support that lipid-lowering therapy, in combination
with other guideline-based medical treatments, maybe as
effective in angina management as percutaneous coronary
intervention (PCI) or bypass surgery in appropriate, lower-
risk patients with stable CHD.
Anti-Atherosclerotic Effects of Statins
It is believed that the anti-ischemic properties of statins are
primarily the result of their favorable effects on vascular
function and atherosclerosis. The prevailing theory on
atherogenesis points to the central roles of LDL and
inflammation in the development of atherosclerosis. The
initiating step is thought to be the oxidation of LDL, which
is subsequently taken up by monocytes. This complex gets
deposited into a dysfunctional vascular endothelium, form-
ing the classic foam cell. This process promotes further
lipid deposition, resulting in atherosclerotic plaque forma-
tion. Progressive plaque accumulation leads to chronic
vessel stenosis, whereas rupture of this atherosclerotic
lesion results in acute vascular syndromes [17, 18].
The statins are the most potent lipid-lowering agents
currently available, and the newer agents have been shown
to reduce LDL levels by up to 55%. Statins lower LDL
primarily through the inhibition of the HMG-CoA-
reductase enzyme, which catalyzes the first committed step
of cholesterol synthesis in the mevalonate pathway. Statins
also decrease triglyceride levels to a lesser degree (up to
20%), presumably through the inhibition of its synthesis in
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the liver and enhancement of lipoprotein lipase enzyme
activity in the adipocytes [19, 20]. In addition, statins also
increase the levels of high-density lipoprotein (HDL), albeit
modestly (up to 10%), the precise mechanism for which
remains unclear. It is postulated that the HDL-raising
properties of statins result from the induction of the
apolipoprotein A1 (Apo-A1) gene through the activation
of peroxisome proliferator–activated receptors [21]. HDL
inhibits the progression of the atherosclerotic process by
facilitating the reverse transport of cholesterol from lipid-
laden monocytes in the vascular wall, and also by
modulating the inflammatory response [17].
Clinical studies have shown that the improvement in
lipid profile seen with statin therapy halts the progression,
and even induces the regression, of atherosclerosis. The
Measuring Effects on Intima-Media Thickness: an Evalua-
tion of Rosuvastatin (METEOR) trial enrolled nearly 1,000
asymptomatic individuals with subclinical atherosclerosis,
who were given either rosuvastatin or placebo [22]. The
study found that, within a relatively short period of time,
statin treatment significantly slowed the rate of increase of
carotid intima-media thickness on ultrasonography, a
change that was evident as early as 12 months within
initiation of therapy [23]. On the other hand, in over 500
patients with known CHD, A Study to Evaluate the Effect
of Rosuvastatin on Intravascular Ultrasound-Derived Cor-
onary Atheroma Burden (the ASTEROID trial) was able to
demonstrate a significant reduction in coronary atheroma
volume and overall plaque burden (measured by intravas-
cular ultrasound) with just 2 years of high-intensity statin
therapy [24].
Statins are able to favorably affect the course of chronic
stable angina presumably by halting or reversing the plaque
buildup responsible for vessel stenosis. In clinical trials,
however, the observed absolute change in percent stenosis
is actually small, and the substantial reductions in clinical
event rates appeared out of proportion to the documented
arteriographic changes [25]. This suggests that the patho-
physiologic mechanisms responsible for chronic stable
angina are different from those involved in acute coronary
events. Statins are thought to prevent acute, unstable
coronary events through stabilization of the “vulnerable
plaque”. The vulnerable plaque is characterized by high
lipid content, increased inflammatory activity, and thin
fibrous cap, which predispose it to disruption and rupture.
Statins deplete the lipid content and also inhibit LDL
oxidation, inflammation, and apoptosis within the athero-
sclerotic plaque. These changes are accompanied by
increased collagen content and expression of anti-
inflammatory mediators. All of these processes represent
the alterations in the molecular structure of the atheroscle-
rotic plaque that favor stability [26]. The phenomenon of
“plaque stabilization” is probably the single most important
basis for the consistent morbidity and mortality reduction
seen in the different statin trials.
Pleiotropic Anti-Ischemic Effects of Statins
Animal studies have demonstrated that chronic statin
therapy can preserve myocardial perfusion and coronary
microvascular permeability independent of lipid lowering
[27]. Such an effect of statins on coronary blood flow was
verified in human studies that utilized myocardial perfusion
imaging (MPI). One trial randomized a small number of
patients with known CHD and average cholesterol levels
into treatment with either pravastatin or placebo for
16 weeks, followed by a cross-over period that lasted
another 16 weeks. Dypiridamole stress radionuclide MPI
testing was performed at the end of each study period.
Analysis of MPI data showed that patients had significantly
smaller perfusion defects on dipyridamole stress testing
while on statin therapy than when on placebo [28]. This
improvement was seen after only a short period of
treatment, suggesting that the benefit derived from statin
therapy is related to functional rather than anatomic
changes.
Another trial prospectively assessed the effects of statin
treatment on the lipid profile and myocardial perfusion in
patients with CHD and dyslipidemia during the first
6 months of pravastatin therapy. Cholesterol levels were
monitored and serial radionuclide MPI were performed at
baseline, at 6 weeks, and at 6 months of statin treatment. At
the end of the follow-up period, half of the subjects showed
significant improvement in myocardial perfusion. The
direction and magnitude of changes in myocardial perfu-
sion did not correlate with improvement in cholesterol
profile, suggesting a lipid-independent phenomenon [29].
Improvement in myocardial perfusion occurs with statin
therapy, even in the absence of arteriographic evidence of
atherosclerotic regression [12]. In addition to the fixed
atherosclerotic obstruction (endothelial dysfunction), it is
likely that dynamic coronary vasoconstriction resulting
from abnormal vasomotor function probably is the domi-
nant factor contributing to episodes of myocardial ischemia.
Coronary angiographic studies have demonstrated a para-
doxical vasoconstrictive response to acetylcholine infusion
in coronary arteries that have minimal obstructive lesions.
This highlights the significance of endothelial dysfunction
in coronary vascular bed where there is early-stage
atherosclerosis, and such phenomenon may indeed contrib-
ute to myocardial ischemia, which is primarily related to
decreased supply rather than increased demand [30]. These
observations reinforce the postulation that certain pleiotro-
pic properties of statins are responsible for their anti-
ischemic properties (Fig. 2).
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Improvement of Endothelial Function by Statins
There is ample experimental evidence pointing to the lipid-
independent effects of statins on endothelial function. In
healthy normocholesterolemic individuals, a single dose of
cerivastatin was shown to significantly increase arterial
flow-mediated dilatation (FMD), a measure of endothelial
function, and this change rapidly returned to baseline 6 h
after statin administration. There were no alterations seen in
the lipid profile and in the indices of endothelium-
independent arterial dilatation, suggesting that cerivastatin
may have a direct vascular effect [31]. Animal models also
show that statins can augment coronary blood flow,
improve cardiac contractile function, and inhibit leuko-
cyte–endothelial cell interactions, primarily by enhancing
the endothelial release of nitric oxide [32]. Nitric oxide
release in endothelial cells is primarily mediated by the
endothelial nitric oxide synthase (eNOS) enzyme. Experi-
mental studies have demonstrated the ability of statins to
enhance the expression, increase the activity, or prevent the
inactivation of eNOS [33].
The experimental findings on the lipid-independent
effects of statins on endothelial function have been
corroborated by clinical data as well. A small trial
randomized 60 dyslipidemic patients without CHD into
treatment with either high-dose simvastatin monotherapy,
combination low-dose simvastatin with ezetimibe, or
placebo [34]. Lipid levels and indices of endothelial
function and vascular inflammation, including C-reactive
protein (CRP), Rho-associated coiled-coil containing pro-
tein kinase (ROCK), and FMD, were measured at baseline
and after 4 weeks. Compared to placebo, both treatment
arms significantly reduced LDL and CRP levels. Signifi-
cant improvement in endothelial function (decreased
ROCK activity and increased FMD) was seen in the high-
dose simvastatin monotherapy group but not with combi-
nation low-dose simvastatin-ezetemibe therapy, despite
similar degrees of LDL and CRP reductions.
The benefit of statins has also been shown in patients
with cardiac syndrome X (CSX), a disorder characterized
by anginal chest pain, positive exercise test, and angio-
graphically normal coronary arteries. CSX is hypothesized
to result from impairment in the normal endothelial
function of the coronary microvasculature, resulting in
inadequate flow reserve. Arterial FMD, as a measure of
endothelial function, was assessed in small trial of 40
normolipidemic patients with CSX who were randomized
into treatment with either pravastatin or placebo. After
3 months of therapy, the statin group showed significant
improvement in FMD, which was accompanied by signif-
icant prolongation in exercise duration and time to
significant ST-depression on stress testing [35]. The
pleiotrophic effect of statins on endothelial function was
presumed to be the primary mechanism responsible for
these findings. These results are clinically relevant as the
majority of women presenting with ischemic-type signs and
symptoms do not have obstructive coronary stenoses but
have impaired coronary vasoreactivity, which has the
potential to limit myocardial flow and may be a predictor
of major adverse outcomes [36].
Anti-Inflammatory Effects of Statins and Ischemia
Using CRP level as a marker of low-grade systemic
inflammation, the Pravastatin Inflammation/CRP Evalua-
tion (PRINCE) trial sought to evaluate the anti-
inflammatory effects of statins in nearly 1,200 patients
with CHD and over 1,700 patients without CHD who were
randomized to receive either pravastatin or placebo for
24 weeks [37]. Statin therapy was shown to significantly
reduce CRP levels by up to 17%, an effect that was evident
as early as 12 weeks. The decrement in CRP levels did not
Fig. 2 Proposed mechanisms
and sites of action for the
anti-anginal and anti-ischemic
effects of statins in coronary
heart disease
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correlate with co-morbid conditions, cholesterol profile, or
change in LDL levels over time, implying that the anti-
inflammatory effects of statins might well be independent
of their lipid-lowering properties.
There are also experimental data that show statins are
able to suppress oxidative stress, primarily those mediated
by protein kinase C and phospholipase D, and that these
effects may be unrelated to lipid-lowering. The protection
from oxidative stress afforded by statins may prevent the
migration of vascular smooth muscle cells in the arterial
wall, which is an important mechanism in atherogenesis
and CHD [38]. In addition, statin treatment has been
demonstrated to inhibit platelet aggregation and thrombus
formation in vascular territories exposed to oxidative stress
[39]. Postulated mechanisms for these anti-thrombotic
effects include enhancement of nitric oxide and cyclic
GMP formation, which are thought to contribute further to
the vasculoprotective properties of statins [40].
Blunting of Ischemia-Reperfusion Injury
Statins improve the vasodilatory response to ischemia most
likely by increasing the extracellular formation of adeno-
sine. Rosuvastatin has been shown to achieve this effect by
enhancing the activity of ecto-5′-nucleotidase, the key
enzyme in extracellular adenosine formation, which results
in improvement of reactive hyperemia in the setting of
ischemia [41]. Through this mechanism, statins may also
interact synergistically with other vasodilating agents to
provide protection against ischemia-reperfusion injury [42].
The clinical implications of these experimental observa-
tions can be inferred from the findings of different clinical
trials on coronary revascularization. In the Novel
Approaches for Preventing or Limiting Events (NAPLES-
II) study, nearly 700 statin-naïve patients who were
scheduled to undergo elective PCI were randomized to
treatment with either single high-dose atorvastatin or
placebo within 24 h of the procedure [43]. The trial found
that a single, loading-dose of statin was associated with a
significant 32% reduction in the incidence of periprocedural
biomarker-defined MI. This result was congruent with an
earlier similar study where over 450 patients undergoing
elective PCI were pre-treated with either statin or placebo at
least 3 days prior to the procedure. After follow-up, the trial
showed a 47% decrease in large Q-wave MI and a 27%
reduction in biomarker-defined MI in the group who
received statins [44].
Near-immediate cardioprotective effects of statins have also
been demonstrated in patients undergoing surgical revascular-
ization. One trial randomized 200 CHD patients scheduled for
coronary artery bypass grafting (CABG) to 1-week pre-
operative treatment with either rosuvastatin or placebo. On
post-operative follow-up, the study found significantly higher
levels of cardiac biomarkers and CRP in those who received
placebo. Myocardial damage was seen more frequently in the
high-risk patients, but the incidence was significantly less in
those who were given rosuvastatin [45].
Conclusions
Improved survival fromMI and CHD has led to an increase in
the number of patients afflicted with chronic angina. Despite
the current state-of-the-art pharmacologic and mechanical
therapies, chronic angina remains a major public health
burden. Evidence is mounting on the anti-ischemic and anti-
anginal efficacy of statins in both experimental and clinical
settings. The pleiotropic effects of statins may be primarily
responsible for their anti-ischemic and anti-anginal properties.
These pleiotropic effects include improvement of endothelial
function, enhancement of the ischemic vasodilatory response,
modulation of inflammation, and protection from ischemia-
reperfusion injury. The anti-ischemic effects of statins further
strengthen their role as a crucial component of the optimal
medical therapy for CHD, and they have been shown to be as
effective as coronary revascularization in the initial manage-
ment of patients with chronic stable angina. The question of
whether or not statins are as potent as the standard classes of
anti-anginal drugs, or as effective in improving ischemia as
certain mechanical strategies, may very well be considered
moot because statin therapy is recommended for all patients
with CHD. However, the knowledge of their anti-ischemic
properties may help reinforce the logic behind treating all our
CHD patients with statins.
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